• Rika Yulia Universitas Surabaya
  • Fauna Herawati Departemen Farmasi Klinis dan Komunitas, Fakultas Farmasi, Universitas Surabaya, Surabaya Indonesia, 60293
  • Klara Rosjuita Hima Mahasiswa Program Studi Farmasi, Fakultas Farmasi, Universitas Surabaya, Surabaya Indonesia, 60293
  • Ruddy Hartono Rumah Sakit Bhayangkara Surabaya HS Samsoeri Mertojoso, Surabaya Indonesia, 60231
  • Puri Safitri Hanum Rumah Sakit Bhayangkara Surabaya HS Samsoeri Mertojoso, Surabaya Indonesia, 60231



Favipiravir, Effectiveness, Side Effects, COVID-19 Pneumonia


Favipiravir's indication extended for COVID-19 disease. This background consideration is related to its mechanism of action or effectivity in some COVID-19 patients, with or without pneumonia. This research is a retrospective observational study and analysis descriptively. The research material is medical records of patients with COVID-19 pneumonia using favipiravir from December 2020-May 2021. A total of 33 samples obtained met the inclusion and exclusion criteria. Effectiveness was analyzed by calculating the percentage of COVID-19 pneumonia patients who only used favipiravir while they were being treated until the patient was discharged. The side effects were the number of COVID-19 patients who drug injury liver disease (AST and ALT increase more than three times upper limit) and neutrophenia. This study reported that favipiravir was effective in COVID-19 patients with pneumonia, seen from 78.79% of patients who only used favipiravir during treatment. There were no patients who had an increase in AST ALT >3×upper limit of normal, and only seven patients with neutropenia.


Barek, M.A., M. A. Aziz., M. S. Islam. 2020. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon;6(12):1-24.

Badan Pengawas Obat dan Makanan (2020) INFORMATOTIUM OBAT COVID-19 DI INDONESIA. BPOM Republik Indonesia

Cai, Q., M. Yang., D. Liu., et al. 2020. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing);6(10):1192-1198.

Chai, X., L. Hu., Y. Zhang., et al. 2020. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoVinfection. BioRxiv.

Chen, C. et al. (2020) Favipiravir versus Arbidol for COVID-19: A randomized clinical trial, medRxiv.

Chen, Y., S. L. Klein., B. T. Garibaldi., et al. 2021. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev;65:101205.

Chowdhury, S.D.,A.M Oommen. 2020. Epidemiology of COVID-19. Journal of Digestive Endoscopy;11(1):3-7.

Dabbous, H.M., S. Abd-Elsalam., M. H. El-Sayed., et al. 2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study. Arch Virol;166(3):949-954.

Instiaty et al. (2020) Antiviral treatment of covid-19: A clinical pharmacology narrative review, Medical Journal of Indonesia, 29(3): 332–345.

Joshi, S. et al. (2021) Role of favipiravir in the treatment of COVID-19, International Journal of Infectious Diseases, 102:501–508. DOI: 10.1016/j.ijid.2020.10.069.

Rozaliyani, A., A. I. Savitri., F. Setianingrum., et al. 2020. Factors Associated with Death in COVID-19 Patients in Jakarta, Indonesia: An Epidemiological Study. Acta Med Indones;52(3):246-254. PMID: 33020335.

Siordia Jr, J. A. et al. (2020) Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials, medRxiv.

Susilo, A., C. M. Rumende., C. W. Pitoyo., et al. 2020. Coronavirus Disease 2019: Tinjauan Literatur Terkini. Jurnal Penyakit Dalam Indonesia; 7(1): 45-67.

PDPI, PERKI, PAPDI, Perdatin, Idai. 2021. Revisi Protokol Tatalaksana Covid-19. Jakarta

Vardavas, C.I., K. Nikitara. 2020. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis;18:20.

Wang, D., Li, Z. and Liu, Y. (2020) An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics, Journal of Infection and Public Health, 13 (2020): 1405–1414.

Wang, J., Q. Li., Y. Yin., et al. 2020. Excessive Neutrophils and Neutrophil Extracellular Traps in COVID-19. Front Immunol;11:2063.

Wang, M., R. Cao., L. Zhang., et al. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res;30(3):269-271.

World Health Organization. 2020. recommends against the use of remdesivir in COVID-19 patients [online].

Yamazaki, S., T. Suzuki., M. Sayama., et al. 2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19. J Infect Chemother;27(2):390-392.

Yousefi, B.,S. Valizadeh.,H. Ghaffari., et al. 2020. A global treatments for coronaviruses including COVID-19. J Cell Physiol;235(12):9133-9142.

Zheng, Z., F. Peng., B. Xu., et al. 2020. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect;81(2):e16-e25.

Zhou, F. et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395(10229): 1054–1062.



How to Cite

Yulia, R., Herawati, F., Hima, K. R., Hartono, R., & Hanum, P. S. (2023). STUDI EFEKTIVITAS DAN EFEK SAMPING FAVIPIRAVIR PADA PASIEN COVID-19 PNEUMONIA DI RUMAH SAKIT BHAYANGKARA SURABAYA. Jurnal Ilmiah Ibnu Sina, 8(2), 307–317.